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ABSTRACT:   
Background: Predictors of thoracic aorta growth and early cardiac surgery in patients with 
bicuspid aortic valve are undefined. Our aim was to identify predictors of ascending aorta 
dilatation and cardiac surgery in patients with bicuspid aortic valve (BAV). 
Methods: Forty-one patients with BAV were compared with 165 patients with tricuspid aortic 
valve (TAV). All patients had LV EF > 50%, normal LV dimensions, and similar degree of aortic 
root or ascending aorta dilatation at enrollment. Patients with more than mild aortic stenosis or 
regurgitation were excluded. A CT-scan was available on 76% of the population, and an 
echocardiogram was repeated every year for a median time of 4 years (range: 2 to 8 years). 
Patterns of aortic expansion in BAV and TAV groups were analyzed by a mixed-effects 
longitudinal linear model. In the time-to-event analysis, the primary end point was elective or 
emergent surgery for aorta replacement. 
Results: BAV patients were younger, while the TAV group had greater LV wall thickness, 
arterial hypertension, and dyslipidemia than BAV patients. Growth rate was 0.46 ± 0.04 
mm/year, similar in BAV and TAV groups (p=0.70). Predictors of cardiac surgery were aorta 
dimensions at baseline (HR 1.23, p= 0.01), severe aortic regurgitation developed during follow-
up (HR 3.49, p 0.04), family history of aortic aneurysm (HR 4.16, p 1.73), and history of STEMI 
(HR 3.64, p < 0.001).  
Conclusions: Classic baseline risk factors were more commonly observed in TAV aortopathy 
compared with BAV aortopathy. However, it is reassuring that, though diagnosed with aneurysm 
on average 10 years earlier and in the absence of arterial hypertension, BAV patients had a 
relatively low growth rate, similar to patients with a tricuspid valve. Irrespective of aortic valve 
morphology, patients with a family history of aortic aneurysm, history of coronary artery disease, 
and those who developed severe aortic regurgitation at follow-up, had the highest chances of 
being referred for surgery. 
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INTRODUCTION 
Bicuspid aortic valve (BAV) is the most common congenital cardiac abnormality in adults, and is 
estimated to be present in 0.5% to 1.5% of the population. Though survival among patients with 
BAV is similar to that of the general population, there is a greater incidence of cardiac and aortic 
complications in these patients1-3. 
An important non-valvular association with BAV is the development of ascending thoracic aortic 
dilatation4,5. We have shown that hemodynamic factors such as shear stress play a key role in 
the pathophysiology of aneurysm dilatation6-8, distinct pathogenetic mechanisms occur with 
BAV9. Moreover, patients with BAV have been shown to have larger aortic diameters than 
controls10. Yet, very few studies have addressed the progression of ascending aortic dilatation 
in BAV patients with respect to those with a tricuspid aortic valve (TAV) and comparable aortic 
size at baseline11. 
Therefore, we investigated the progression pattern of ascending aortic dilatation by assessing 
the influence of predisposing factors, such as aortic valve morphology and its variation at follow-
up using both clinical and echocardiographic variables. Specifically, we aimed to test whether 
growth curve trajectories of the aortic diameter differ in BAV patients versus TAV patients, and 
to identify independent predictors of surgery for ascending aortic dilatation.  
  
METHODS 
Study Population  
One thousand three-hundred forty-two consecutive (1,342) patients from our outpatient clinic 
and referred for elective surgery for ascending aortic dilatation from 2000 to 2017 at our institute 
were retrospectively reviewed for recruitment. Inclusion criteria were left ventricular ejection 
fraction (LV-EF) > 50 %, maximal aortic diameter indexed to BSA > 2.1 cm/m2, and 
echocardiographic follow-up with at least 2 examinations 1 year apart. Exclusion criteria at 
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baseline were evidence of uncontrolled stage II/III hypertension (blood pressure > 160/95 
mmHg); LV dilatation, as defined by LV end-diastolic diameter ≥ 55 mm; more than moderate 
mitral or tricuspid valve disease;  previous history of cardiac surgery; acute and chronic aortic 
dissections; aortic dilatation associated with significant congenital or acquired cardiac diseases 
(i.e., untreated or recurrent aortic coarctation), or genetic screening positive for systemic 
syndromes (i.e., Marfan, Loeys-Dietz, Ehler-Danlos, Turner). However, a family history of aortic 
aneurysm was not an exclusion criterion. The study was approved by our Institutional Research 
Review Board. 
After exclusions, a total of 206 patients comprised the study group, with available data at 
baseline and follow-up. Standard demographic, clinical, and echocardiographic data were 
collected, as well as chest CT measurements of the aorta when available (N=156, 76%, with no 
missing data for the echocardiographic imaging) at each follow-up visit. 
Echocardiography  
Transthoracic echocardiograms were analyzed de novo and then reviewed by a reader blinded 
to clinical outcomes (D.B.). All echocardiographic examinations were performed with a 
commercially available instrument (Vivid E90 System; Vingmed, General Electric, Milwaukee, 
Wisconsin). Standard LV systolic and diastolic parameters from 2D and Doppler 
echocardiography were acquired and measured, as previously described12.  
Severity of aortic stenosis was graded by integration of Doppler methods, continuity equation, 
and planimetry. Aortic regurgitation (AR) degree was defined as composite evaluation of 
proximal jet vena contracta, pressure half-time of the regurgitant jet, diastolic reverse flow 
duration and end-diastolic maximal velocity in ascending thoracic aorta, and LV end-diastolic 
dimension13, 14. BAV was defined as a systolic fish-mouth appearance of the orifice in 
parasternal short-axis views15. 
The aorta was measured twice (leading-edge to leading-edge method) by bidimensional 
imaging16 in parasternal long-axis views at the root (maximal dilation of the sinuses of Valsalva) 
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and ascending aorta at the maximal diameter. The tubular tract was routinely visualized at least 
2 to 3 cm distal to the sino-tubular junction (STJ). 
Outcome measures 
Aortic growth rate was defined as the difference between the diameter at presentation and the 
diameter at baseline in-hospital admission, divided by the follow-up time interval in years. The 
primary end point was surgical operation of the aorta and/or aortic valve for elective referral as 
assessed by hospital chart review (100% completeness of data). Patients admitted for emergent 
aortic surgery or with acute aortic dissection were excluded by study design. Mortality data were 
obtained from review of medical records or observation of death certificate with subsequent 
confirmation from a family member. Cardiovascular death due to aortic rupture occurred in one 
patients while noncardiac deaths were observed in three patients (ie, two malignancies and one 
hepatitis). Emergent surgical repair of aneurysmal aorta was observed in one patient treated out 
of our hospital institution.    
  
Statistical Analysis 
Initially, two-way repeated measures analysis of variance (time-group interaction) was 
performed using STATA version 15.1 (Stata-Corp LP, College Station, TX). The two groups 
stratified according to aortic valve morphology (BAV vs TAV) were the between-subjects factor 
(group), while the repeated measurements of the aorta during follow-up were the within-subjects 
factor (time). A Greenhouse–Geisser correction was used for sphericity17. This was done for 
aortic size evaluations as well as demographic, clinical, and echocardiographic measures within 
and between patients with either BAV or TAV.  One-way repeated measures analysis of 
variance with a two-tailed post-hoc Tukey mean comparison tests was done to test change from 
baseline within each group. Unpaired two-sided Student's t-test or a Fisher’s exact test were 
used to a) compare baseline conditions of BAV versus TAV patients and b) compare groups 
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stratified according to clinical indication (patients referred for surgery vs. patients not referred to 
surgery). 
Subsequently, linear growth curve parameters of aortic root and ascending aortic dimensions 
measured yearly by echocardiography were estimated by a random-effects mixed model, 
implemented in R Software, version 3.3.4 (R Foundation for Statistical Computing, Vienna, 
Austria. URL https://www.R-project.org/)18. Model selection was based on Akaike’s information 
criterion19. 
Finally, univariate as well as multivariable time-to-event analysis by Cox proportional-hazards 
models was done to assess prognostic usefulness of demographic, clinical, and 
echocardiographic measures in defining risk for surgery. Given the longitudinal design of our 
study, most of collected variables changed over time during follow-up, and such time-varying (or 
time-dependent) covariates were accounted for when included in the Cox regression analysis20. 
At the beginning, the proportional hazards assumption was tested by examining the residuals of 
each model so that, for each time-dependent covariate, two different values of hazard ratio (and 
relative p-value) were obtained. The first referred to the “main effect,” and was therefore the 
prognostic significance of the covariate considering its value at baseline as in a standard Cox 
analysis. The second hazard ratio (and p-value) was the “time-varying effect,” and was the 
prognostic significance of the change over time of predictors determining primary outcome21. 
Multivariable survival analysis was done with stepwise mixed (backward and then forward) 
strategy, including predictors with p-value ≤ 1.0 according to simple survival analysis.   
  
RESULTS 
Demographic, Clinical and Echocardiographic Characteristics of the Study Population 
Out of 206 patients included in this study, 165 patients (80%) had TAV, while BAV was found in 
41 patients (20%). Ascending aortic replacement was performed in 30 patients (15%) at a 
median follow-up of 5 years in the range of 2-13 years from initial screening.  
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Patient demographics are summarized in Table 1. At baseline hospital admission, BAV patients 
were significantly younger than TAV patients (57±12 years for BAV, and 69±9 years for TAV, p-
value<0.001). Though biometrics, blood pressure, and heart rate were comparable between 
groups at both baseline and serial evaluations, the baseline measurement of LV wall thickness 
of the anteroseptum was larger in TAV patients with respect to BAV patients. Prevalence of 
arterial hypertension, dyslipidemia, and mild-to-moderate mitral regurgitation at enrollment of 
TAV patients was higher than that of BAV patients. LVEF and LV dimensions/volumes, as well 
as trans-mitral flow measures were comparable between the groups at both baseline in-hospital 
admission and surveillance imaging.   
With regard to aortic sizes (Table 2), initial in-hospital measurements of both aortic root and 
ascending aortic dimensions were high by study design, but there was no statistically significant 
difference in the mean values between BAV and TAV patient groups (i.e., 45.3±3.5mm for BAV-
related ascending aortic diameter vs. 45.8±3.8mm for TAV-related ascending aortic diameter, 
p=0.70, and 39.5±6.4mm for BAV-related aortic root diameter vs. 41.4±5.6mm for TAV-related 
aortic root diameter). During serial evaluation, aortic dilatation increased significantly in both 
groups similarly, so that interaction of group by time was not significant (Figure 1).  
 
Linear Growth Models: Aortic Aneurysm Progression over Time  
For the entire study population, a linear mixed model with time as single predictor (as both fixed 
and random effect) showed that the ascending aorta dilated at a growth rate = 0.46 ± 0.04 mm / 
year, with an average rate of 1.33 ± 0.04% / year for the whole follow-up time. The actual 
growth rate per year was high at the first and second year (2.5%) then decreased steadily from 
third year to end of follow-up as shown by Table 2 and Figure 2. Similar growth rates were 
found when analysis was repeated for BAV patients versus TAV patients (average growth rate = 
1.4% for TAV patients, and 1.2% per year for BAV patients). When considering time, the model 
with the highest fit to observed data was a quadratic polynomial linear growth model that 
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included time and squared time (time2) as both fixed and random effects (Table 3a). The 
inclusion of aortic valve morphology (i.e., grouping variable) did not improve prediction (p-value 
= 0.44).  
When demographic, clinical and echocardiographic variables were added one by one to the 
unconditional model, ascending aortic dimensions at baseline (p-value < 0.001), development of 
moderate-to-severe aortic regurgitation during follow-up (β = 3.81 ± 0.67, p-value < 0.001), LV 
wall thickness of the anteroseptum (β = 0.16 ± 0.06, p-value 0.006), use of a β-blocker (at any 
effective dosage, β = -0.61± 0.30 p-value 0.03), and use of aspirin (100 mg PO daily, β = 0.60 ± 
0.30 p-value 0.04) were all significant predictors of change in aortic dimensions during 
surveillance. 
Finally, according to multivariable analysis done by forcing both time and time2 into the model, 
ascending aortic diameter at baseline, development of severe aortic regurgitation during follow-
up, and the use of a β-Blocker were the only independent predictors of aortic dimensions over 
time (Table 3b).  
  
Predictors of Cardiac Surgery  
During the study period, aortic replacement was performed in 4 patients (10%) with BAV, and 
26 patients with TAV (16%, p-value=0.46).   
At baseline, patients referred for surgery had greater aortic dimensions independent of aortic 
valve morphology at either root level or ascending tubular tract compared with non-surgically-
treated patients (Table 4). In addition, patients referred for surgery had higher LV end-diastolic 
dimensions (index), and greater prevalence of moderate-to-severe aortic regurgitation 
developed during follow-up compared with patients who did not undergo surgery. Surgically-
treated patients had also higher proportion of family history of aortic aneurysm, greater 
prevalence of coronary artery disease (specifically history of ST elevation myocardial infarct) 
compared with non-surgically treated patients. Most importantly, patients referred for surgery 
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developed moderate-to-severe mitral regurgitation during follow-up, and used a higher 
proportion of beta-blocker more frequently than the non-surgical group.  
Table 4 shows hazard ratios and p-values for simple (univariate) Cox analysis. BAV patients 
had a significantly lower risk of being referred for surgery compared with TAV patients, as 
shown in Figure 3. On the other hand, patients with lower body surface area, greater 
dimensions of aortic root (index), ascending aorta, as well as LV at baseline had the greatest 
risk of being referred for surgery. Likewise, patients who developed severe aortic regurgitation 
during follow-up, and those with a family history of aortic aneurysm, ischemic cardiomyopathy, 
ST elevation myocardial infarct, transitory ischemic attack, or pacemaker / ICD implant, had the 
highest chances of undergoing surgical repair of dilated aorta. Considering time-varying 
covariates, change in aortic dimensions during follow-up, as well as change in LV wall thickness 
or LV dimensions during follow-up did not modify risk of being referred for cardiac surgery.  
According to multivariable analysis, independent predictors of cardiac surgery referral for aortic 
replacement were as follows: aortic root, as well as ascending aorta dimensions at recruitment 
(HR 1.23, p 0.01 and HR 1.38 p-value < 0.001, respectively), severe aortic regurgitation 
developed during follow-up (HR 3.49, p-value = 0.04), family history of aortic aneurysm (HR 
4.16, p-value = 0.03), and history of ST elevation myocardial infarct (HR 3.64, p-value < 0.001).  
  
DISCUSSION 
To the best of our knowledge, this is the first study to describe progression of ascending 
thoracic aortic aneurysms in stable outpatients with chronic aortic aneurysm to compare 
differences between BAV and TAV patients and, at the same time, to identify independent 
factors to consider for referring this population for surgery of dilated aorta.   
The principal findings of this investigation are here described: 1) ascending aortic dilatation 
measurements at baseline and growth rates of aortic size in a time range of 8 years were 
comparable between TAV and BAV patients; yet, BAV patients were younger and free of 
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cardiovascular risk factors aortas compared with TAV patients; 2) the aorta dilated primarily in 
the first 2 years after diagnosis, then reached a plateau, and remained substantially stable over 
the 8-year follow-up period; 3) β-blocking therapy was associated with the progression of aortic 
dilatation, apparently reducing growth rate, and  4) aortic dimensions at baseline, family history 
of aortic aneurysm, and the development of severe aortic regurgitation or an ST elevation 
myocardial infarct during follow-up, but not the aortic valve morphology itself, were the most 
important predictors of aortic replacement in the long term.  
In healthy adults, aortic diameter does not usually exceed 40 mm, and is variably influenced by 
several factors, including age, gender, body size, and blood pressure. Overall, the rate of 
ascending aortic progression in our study population was 0.5 mm per year, that is, slightly more 
than 1% per year. These data are reassuring, and consistent with previous reports focused on 
either TAV 22, 23 or BAV patients 11, 24, 25. 
High blood pressure is a well-known risk factor for the development of aortic dilatation, and it is 
not surprising that patients with TAV and aortic aneurysm had increased LV wall thickness 
compared with dilated aorta with BAV. On the other hand, though BAV patients had aortic 
enlargement similar to that of TAV at baseline, this was not associated with arterial 
hypertension, dyslipidemia or other known cardiovascular risk factors. Indeed, the larger aortic 
diameters in patients with BAV may be a result of longer periods of exposure to increased aortic 
shear stress in patients born with a congenital anomaly, as opposed to acquired disorders, such 
as hypertension or atherosclerosis. Looking at growth trajectories grouped according to valve 
morphology, the aorta expanded in both groups, with a similar trend. However, diagnosis of 
aortic dilatation in BAV occurred 10 years earlier than in TAV. Therefore, in the BAV group, 
other factors, including altered hemodynamics secondary to abnormal valve morphology or 
genetic predisposition leading to a defect in the aortic wall structure may have dramatically 
influenced the progression of aortic dilatation, and are definitely more influential than standard 
risk factors26.  
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It is also noteworthy that yearly growth rate was highest in the first 2 years (i.e., 2.5% at 1-year 
follow-up, and 1% at 2-year follow-up), but then decreased substantially from the third year on, 
reaching a plateau (0.2% and 0.7% at the 8th year for TAV and BAV, respectively), thereby 
justifying the use of a quadratic polynomial model to best describe the trajectory of aortic 
enlargement.  
This favorable trend is significantly different from that observed in other congenital aortopathies, 
such as Marfan syndrome or degenerative aortopathy11, and is likely influenced by several 
factors, among which a timely established therapy. In fact, according to our analysis, beta-
blockers were the only drug to have a significant effect on modifying aortic enlargement over 
time. This protective effect of beta-blocking has been found in specific groups of patients with 
aortic aneurysms, for example in the setting of Marfan syndrome27 28, and though our data seem 
to confirm the role of beta-blockers in delaying or even preventing aortic expansion independent 
of aortic valve morphology, at this time a causal effect involving such medication can only be 
hypothesized, due to the retrospective nature of this study. It is also possible to speculate that 
the beneficial effect provided by beta-blockers could act differently in TAV patients compared 
with BAV patients: in the former group, arterial hypertension is a primary risk factor for 
aneurysm enlargement, and therapy with beta-blockers can help in preventing high blood 
pressure peaks. Beta-blockers could be beneficial even in younger patients with BAV but 
without arterial hypertension, providing a well-recognized cardio-protective action and reducing 
hemodynamic loads induced by the development of valvulopathies during the life course (i.e., 
aortic stenosis or aortic regurgitation), which are common in these patients.  
Considering the predictors of referral for surgery for aortic repair, it is not surprising that aortic 
dimensions at diagnosis (either at root or at tubular ascending level) were among the most 
significant and independent determinants of adverse outcome. It is interesting to note that 
changes in the aortic size at follow-up in our population were negligible; in fact, patients who 
were not referred for surgical replacement within the first 2 years of diagnosis underwent 
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cardiac surgery for super-imposed cardiac comorbidities, including the development of severe 
aortic regurgitation (requiring valve surgery) or coronary artery disease, and STEMI in particular 
(requiring coronary-artery bypass graft). Once the indication for surgery was given, replacement 
of the ascending aorta is usually (and understandably) performed to prevent risk of new surgery 
after some time. This secondary repair of the aorta is quite common, and consistent with most 
recent guidelines29. It is also reassuring that patients with no cardiac pathologies beyond aortic 
enlargement have a reduced risk of undergoing surgery after the first 2 years from diagnosis. 
These findings reflect a general change toward a more conservative approach to BAV-
associated aortopathy compared with previous guidelines, which stated that such patients 
should be managed as aggressively as those with connective tissue disorders30.  
Avadhani et al. highlighted the association between aortic valve disease and high growth rate at 
follow-up, specifically in BAV patients24. Furthermore, Della Corte et al. suggested that aortic 
stenosis would be a protective factor of aortic root enlargement, at the same time exposing the 
patient to mid-ascending aorta to dilatation
31
, while a recent study by Evangelista et al. of 852 
patients with BAV found that significant aortic regurgitation at baseline was associated with 
enlarged aortic root, but not with ascending aorta dilatation
32
. These above-mentioned findings 
cannot be corroborated by our investigation since by study design our population did not include 
patients with moderate to severe valvulopathy at baseline. However, as found in Evangelista et 
al.  we can confirm that BAV patients have enlarged ascending aorta at baseline in the absence 
of significant aortic valve stenosis or regurgitation, and that the development of severe aortic 
regurgitation at follow-up is an independent predictor of both aortic enlargement during follow-up 
as well as referral for surgical repair, as reported by Della Corte et al.25, and in our previous 
study33. 
Isolated enlargement of the aortic root was reported as an independent predictor of faster aortic 
expansion, specifically in BAV patients25. In our cohort, BAV patients had only a small 
enlargement of the aortic root compared with the TAV group, and the number of patients with an 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
isolated dilatation of the aortic root was too small to be analyzed separately. It may be that 
differences in the aortic root and mid-ascending aortic growths over time apply specifically to 
patients with a significant valve disease at baseline. 
Though family history of an aortic aneurysm in our study population was not a predictor of the 
expansion rate of the aorta during follow-up, this was an independent predictor of surgery, being 
associated with a greater enlargement diagnosed at initial in-hospital admission. This finding 
highlights the significant role of a thorough family history in defining overall risk of surgery in 
patients with aortic aneurysms, and is consistent with the most recent guidelines29,34. 
Furthermore,  we recently demonstrated how epigenetic (micro RNAs profiling) information can 
be used in this population35 to discriminate the severity of ascending aortic dilatation from 
circulating blood. Therefore, we remark that a deeper work-up, including formal genetic and 
epigenetic screening for known mutations exposing the aorta to severe enlargement should be 
routinely performed in patients with aortic aneurysm at first diagnosis and, in particular, in those 
with BAV. 
Study Limitations  
Our study has several limitations. Baseline measurements of dilated aorta refer to the first 
echocardiogram (or CT scan) performed to reach a definitive diagnosis, and is therefore 
necessarily arbitrary. Since growth rates are computed from that specific time point, trajectories 
can be influenced by the time the patient entered the study. However, since we have completed 
a long-term follow-up (up to 13 years) the left truncation effect should be negligible.  Such a 
study does not apply to patients with demonstrated genetic causes of aortic aneurysms, such as 
Marfan, Loeys-Dietz, Ehlers-Danlos, or Turner syndromes since the term “family history of aortic 
aneurysm” was general and not specific of the type of genetic disorders. Information on the 
BAV-related phenotype were not included in this study because other reports have 
demonstrated that leaflet orientation was not helpful in determining rate of aorta expansion24; 
moreover,  subsetting groups of BAV patients into additional subgroups would have affected the 
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statistical power of the study. Though we collected aortic size measurement also by CT scan, 
these were not available for all patients, and just for one or two time points at follow-up, since 
echocardiographic surveillance is preferred over CT imaging. Moreover, also considering 
potential disagreement between the two imaging techniques36,37, and in order to avoid likely 
inconsistencies, CT imaging was used solely to identify patients with a diagnosis of aortic 
aneurysm, but aortic dimensions were measured and analyzed exclusively by echo, either at 
baseline or at each follow-up visit.  Our study was focused on patients with chronic and stable 
aneurysm of dilated aorta either with a TAV or BAV, who underwent regular follow-up, and were 
referred (or not) for elective cardiac surgery, so that findings cannot be applied to patients 
presenting with acute aortic dissection or requiring emergent surgery.  
  
CONCLUSIONS 
Pathophysiology of aortic aneurysm in BAV patients is substantially different from that observed 
in TAV patients, where classic risk factors such as arterial hypertension or dyslipidemia are of 
utmost importance. Though diagnosed with aneurysm on average 10 years earlier in the 
absence of arterial hypertension, BAV patients had relatively low growth rates, different from 
other congenital aortopathies and similar to TAV patients. Irrespective of aortic valve 
morphology, patients with a family history of aortic aneurysm, history of coronary artery disease, 
and those who developed severe aortic regurgitation during surveillance had the highest 
chances of being referred for surgical repair of the dilated aorta. To improve the clinical 
decision-making process, timely anti-hypertensive therapy in all patients with high blood 
pressure, preferably including a beta-blocker, specifically in patients with known aortic 
enlargement is highly recommended. Further prospective studies enrolling a larger sample of 
BAV patients, randomized to either placebo or beta-blocking therapy are warranted to confirm 
the protective effect of beta-blockers in this population, even in the absence of arterial 
hypertension.  
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Table 1: Demographic, clinical, and echocardiographic characteristics 
Variable 
Group I  
(TAV) 
Group II  
(BAV)  p-values (Repeated Measure ANOVA) Longitudinal Mixed Effects Models  
Mean ± SD (N = 165) (N = 41) Between Groups Within Group (Time) Between * Within  p-values AIC 
p-value  
per Group 
Age (Years) 69 ± 9.4 57 ± 12.2 < 0.001 0.881 0.811 < 0.001 3584.6 0.05 
Males  (N (% )) 139 (84) 34 (83) 0.8150     0.82 3623.5 0.41 
Height (cm) 169.93 ± 8.1 172.71 ± 7.3 0.2151 0.968 0.988 0.61 3623.3 0.45 
Weight (Kg) 82.32 ± 13.6 82.34 ± 15.2 0.9658 0.413 0.266 0.46 3623.0 0.40 
BMI 28.44 ± 3.9 27.48 ± 4 0.3873 0.428 0.496 0.32 3622.5 0.45 
BSA 1.92 ± 0.2 1.94 ± 0.2 0.5856 0.180 0.195 0.46 3623.0 0.39 
Smoke (N (% )) 22 (78.6) 6 (21.4) 0.8020     0.88 3623.5 0.41 
Systolic Blood Pressure (mmHg) 130 ± 16.3 128 ± 15.5 0.6861 0.086 0.156 0.97 3623.5 0.41 
Diastolic Blood Pressure (mmHg) 73.69 ± 12.3 75.15 ± 12.1 0.4491 0.831 0.556 0.17 3621.6 0.43 
Heart Rate (bpm) 69.23 ± 13.9 74.42 ± 14.8 0.3429 0.967 0.891 0.61 3623.3 0.40 
Previous Aortic Surgery  (N (% )) 26 (16) 4 (9.7) 0.4590 
  
< 0.001 3595.1 0.63 
Family History of Aortic Aneurysm (N (% )) 29 (18) 7 (17) 1.0000 
  
0.91 3623.5 0.41 
Atrial Fibrillation  (N (% )) 11 (7) 1 (2.4) 0.4670 
  
0.88 3623.5 0.40 
Ischemic Cardiopathy  (N (% )) 4 (2) 1 (2.4) 1.0000 
  
0.25 3622.2 0.41 
Cardiomyopathy  (N (% )) 1 (0.6) 0 (0.0) 1.0000 
  
0.11 3620.9 0.44 
Chronic Kidney Disease  (N (% )) 2 (1.2) 0 (0.0) 1.0000 
  
0.71 3623.4 0.42 
Chronic Obstructive Pulmnary Disease  (N (% ) 3 (2) 1 (2.4) 1.0000 
  
0.49 3623.0 0.41 
Hypertension  (N (% )) 139 (87.4) 20 (49) < 0.001 
  
0.35 3622.7 0.59 
Diabetes  (N (% )) 15 (9.1) 2 (4.4) 0.5340 
  
0.09 3620.7 0.36 
Dyslipidemia  (N (% )) 45 (28) 4 (8.2) 0.0230 
  
0.84 3623.5 0.40 
Implantable Cardioverter Defibrillator  (N (% )) 4 (2) 1 (2.4) 1.0000 
  
0.22 3622.0 0.41 
STEMI  (N (% )) 9 (5.4) 1 (2.4) 0.6900 
  
0.44 3622.9 0.43 
Stroke  (N (% )) 2 (1.2) 0 (0.0) 1.0000 
  
0.75 3623.4 0.42 
Statin  (N (% )) 54 (33) 9 (22) 0.2550 
  
0.28 3622.3 0.45 
ACE inhibitor  (N (% )) 108 (65) 18 (44) 0.0130 
  
0.44 3622.9 0.46 
Alpha-blocker  (N (% )) 9 (5.4) 5 (12) 0.1600 
  
0.77 3623.4 0.42 
Antiaggregant  (N (% )) 16 (9.7) 3 (7.3) 0.7710 
  
0.77 3623.4 0.41 
Anticoagulant  (N (% )) 17 (85.0) 3 (7.3) 0.7700 
  
0.26 3622.3 0.43 
Acetylsalicylic acid  (N (% )) 51 (83.6) 10 (24.4) 0.4520 
  
0.04 3619.3 0.47 
Beta blocker  (N (% )) 63 (87.5) 9 (22) 0.0670 
  
0.03 3619.0 0.34 
Calcium channel blocker  (N (% )) 43 (86.0) 7 (41) 0.3090 
  
0.34 3622.6 0.44 
Digoxin  (N (% )) 1 (0.6) 1 (2.4) 0.3590 
  
0.51 3623.1 0.38 
Diuretics  (N (% )) 27 (16) 4 (8.2) 0.3400 
  
0.62 3623.3 0.42 
Transient ischemic attack  (N (% )) 2 (1.2) 0 (0.0) 1.0000 
  
0.25 3622.2 0.44 
Ant-Septum Thickness (mm)  12.15 ± 1.7 10.21 ± 4.3 0.0007 0.656 0.816 0.01 3616.0 0.73 
Posterior Wall Thickness (mm) 10.88 ± 3.9 10.43 ± 2.7 0.7336 0.590 0.798 0.52 3623.1 0.40 
LV ED Diameter Index (mm/cm2) 24.45 ± 3.1 23.47 ± 3.4 0.5529 0.432 0.572 0.25 3622.2 0.43 
LV  ED Diameter (mm) 46.74 ± 5.9 45.18 ± 5.4 0.3006 0.484 0.714 0.17 3621.6 0.43 
LV ED Volume Index (mL/cm2) 54.02 ± 13.6 53.51 ± 11.4 0.7211 0.087 0.558 0.67 3623.3 0.41 
LV ED Volume (mL) 106.45 ± 27.7 103.99 ± 24.6 0.4592 0.169 0.458 0.48 3623.0 0.41 
LV ES Volume Index (mL/cm2) 21.53 ± 8.2 21.07 ± 7.8 0.8847 0.093 0.855 0.18 3621.7 0.40 
EF  (% ) 60.97 ± 4.6 60.74 ± 3.7 0.4769 0.337 0.095 0.70 3623.4 0.41 
Mitral regurgitation (mild-moderate) 90 (88.2) 12 (11.8) 0.0050     0.98 3623.5 0.41 
E wave Velocity (mt/sec) 0.45 ± 5.4 0.98 ± 4.7 0.6300 0.490 0.578 0.41 3622.8 0.42 
A Wave Velocity (mt/sec) 0.18 ± 5.4 0.24 ± 5.6 0.9240 0.358 0.459 0.49 3623.0 0.42 
E Wave Deceleration Time (msec) 237.48 ± 55.9 238.63 ± 54.5 0.2661 0.507 0.416 0.96 3623.5 0.41 
E/A Ratio 1.26 ± 6.3 0.66 ± 2.6 0.7127 0.503 0.893 0.83 3623.5 0.40 
Tricuspid regurgitation (mild-moderate)  (N (% )) 100 (83.3) 20 (16.7) 0.2150     0.14 3621.4 0.43 
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Table 2: Aortic dimensions by time and group 
 
  Baseline 1 yr 2 yr 3 yr 4 yr 5 yr 6 yr 7 yr 8 yr p-values 
          
Between Groups Within Group (Time) Between * Within  
TAV             
Aortic Root 41.4 ± 5.6 42.4 ± 5.3 43 ± 5 43.9 ± 5.1 44.4 ± 4.8 44.6 ± 5.2 46.6 ± 5.1 46.7 ± 3.7   0.144 < 0.001 0.791 
Grow th Rate (%)  
 
2.9 ± 6.8 1.1 ± 3.0 1.2 ± 2.5 0.7 ± 2.0 0.6 ± 2.9 -0.2 ± 0.8 0.5 ± 1.1 
    Ascending Aorta 45.8 ± 3.8 46.8 ± 4.2 46.8 ± 3.6 47 ± 3.5 47.6 ± 3.7 47.7 ± 4.6 47.7 ± 4.4 47.7 ± 4.3  0.702 < 0.001 0.962 
Grow th Rate (%)  
 
2.4 ± 8.1 1.0 ± 1.8 0.8 ± 1.9 0.7 ± 1.6 0.3 ± 0.7 0.1 ± 0.6 0.1 ± 1.0 
    BAV 
            Aortic Root 39.5 ± 6.4 40.2 ± 6.5 40.3 ± 6.6 40.2 ± 6.3 41.8 ± 4.7 41.9 ± 5.3 42 ± 5.3 42 ± 5.5 42.1 ± 5.7 
   Grow th Rate (%)  
 
1.8 ± 3.4 1.6 ± 3.0 0.6 ± 1.7 0.8 ± 2.4 0.5 ± 2.0 0.0 ± 0.0 0.0 ± 0.0 1.9 ± 3.2 
   Ascending Aorta 45.3 ± 3.5 46.2 ± 3.6 46.6 ± 3.1 46.9 ± 3.1 46.7 ± 2.7 47.6 ± 2.5 48.5 ± 1.7 48.7 ± 1.4 48.9 ± 1.1 
   Grow th Rate (%)  
 
2.4 ± 4.6 1.0 ± 1.7 0.7 ± 1.6 0.6 ± 1.5 0.5 ± 1.1 0.5 ± 1.4 0.3 ± 0.8 0.2 ± 1.2 
   
  Indexed values (mm / cm2)       
TAV 
            Aortic Root 24.02 ± 2.83 24.6 ± 3.28 24.38 ± 2.71 24.47 ± 2.76 24.2 ± 2.2 24.22 ± 2.31 23.58 ± 1.9 23.19 ± 2.34  0.533 < 0.001 0.773 
Ascending Aorta 24.02 ± 2.83 24.6 ± 3.28 24.38 ± 2.71 24.47 ± 2.76 24.2 ± 2.2 24.22 ± 2.31 23.58 ± 1.9 23.19 ± 2.34   0.533 < 0.001 0.773 
BAV 
            Aortic Root 23.56 ± 2.99 23.92 ± 3.08 24.2 ± 2.92 24.69 ± 3.29 24.27 ± 2.84 24.57 ± 3.03 26.21 ± 2.28 25.8 ± 3.02 26.38 ± 3.49 
   Ascending Aorta 23.56 ± 2.99 23.92 ± 3.08 24.2 ± 2.92 24.69 ± 3.29 24.27 ± 2.84 24.57 ± 3.03 26.21 ± 2.28 25.8 ± 3.02 26.38 ± 3.49     
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Table 3a: Unconditional Linear Growth Model, Fixed and Random Intercept, Time and Time2 
 
 
Ascending Aorta Dimensions β (Std.Err) [95% Conf. Interval] p-value 
Intercept 45.7 (0.26) 45.16 < 0.001 
Timewave 1.12 (0.23) 0.68 < 0.001 
Timewavesqr -0.13 (0.04) -0.2 0 
 
 
Table 3b: Final Multivariable Growth Model for Ascending Aorta Dilataton by Time 
 
Predictor β (Std.Err) p-value 
Aortic dimension at Baseline (mm) 45.68 ( 0.29 ) < 0.001 
Time 1.04 ( 0.15 ) < 0.001 
Time2 0.05 ( 0.01 ) < 0.001 
β-Blockers -0.6 ( 0.28 ) 0.04 
Severe Aortic Regurgitation 4.07 ( 1.9 ) 0.03 
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Table 4: Study population characteristics: grouped by cardiac surgery 
 
Variable  No Surgery Surgery p-value Main Effect Time-Varying Effect 
(Mean ± SD) (N = 177) (N = 30)   HR p-value HR p-value 
Age (y ears) 66.69 ± 11.04 69.14 ± 11.10 0.271 1.03 0.12     
Height (cm) 171.03 ± 7.96 167.10 ± 7.34 0.014 0.94 0.00     
Weight (kg) 82.78 ± 14.20 79.53 ± 11.92 0.244 0.98 0.09     
BMI 28.22 ± 3.98 28.43 ± 3.44 0.796 1.01 0.92     
BSA 1.93 ± 0.19 1.87 ± 0.16 0.085 0.10 0.02     
Sy stolic Blood Pressure (mmHg) 131.18 ± 15.85 123.93 ± 16.73 0.025 0.99 0.20     
Diastolic Blood Pressure (mmHg) 74.42 ± 12.19 71.36 ± 12.69 0.214 0.98 0.21     
Heart Rate (bpm) 70.40 ± 13.93 69.39 ± 15.97 0.722 0.99 0.43     
Ascending Aorta 45.36 ± 3.66 47.41 ± 3.78 0.006 1.50 < 0.001 1 0.13 
Ascending Aorta Index  23.66 ± 2.78 25.53 ± 2.88 0.001 1.47 < 0.001 1 0.24 
Aortic Root 41.17 ± 5.55 40.03 ± 7.25 0.331 1.00 0.93 1 0.98 
Aortic Root Index  23.66 ± 2.78 25.53 ± 2.88 0.001 1.47 < 0.001 1 0.93 
Ant-Septum Thickness (mm)  11.79 ± 2.74 11.60 ± 1.18 0.719 1.10 0.31 1 0.69 
Posterior Wall Thickness (mm) 10.97 ± 3.33 9.73 ± 5.36 0.095 0.97 0.45 1 0.2 
LV ED Diameter (mm) 46.26 ± 5.70 47.51 ± 6.38 0.283 1.03 0.33 1 0.42 
LV ED Diameter Index  (mm /  cm2) 24.04 ± 3.00 25.56 ± 3.79 0.016 1.15 0.01 1 0.73 
LV ED Volume (mL) 104.49 ± 28.49 101.45 ± 23.65 0.587 0.99 0.39 1 0.35 
LV ED Volume Index  (mL/cm2) 53.87 ± 13.49 54.18 ± 11.12 0.909 1.00 0.94 1 0.12 
LV ES Volume Index  (mL/cm2) 21.72 ± 7.72 19.70 ± 10.15 0.215 0.97 0.21 1 0.64 
LV Ejection Fraction (%) 60.99 ± 4.32 60.52 ± 4.97 0.594 0.92 0.06 1 0.66 
E w av e Velocity (mt/sec) 0.76 ± 4.23 -0.66 ± 9.22 0.177 0.98 0.45     
A Wav e Velocity  (mt/sec) 0.05 ± 4.71 -0.31 ± 8.55 0.742 0.99 0.86     
E Wav e Deceleration Time (msec) 239.52 ± 54.12 226.65 ± 63.12 0.248 1.00 0.59     
E/A Ratio 1.02 ± 5.63 1.83 ± 6.46 0.483 1.01 0.72     
Categorical Variables 
Male  (N (%)) 151 ± 85.8 22 ± 73.3 0.147 0.54 0.14     
Bicuspid Aortic Valve (N (%)) 37 ± 21.0 4 ± 13.3 0.467 0.26 0.02     
Aortic Regurgitation (Mild-Moderate) 9 ± 5.1 5 ± 16.7 0.053 4.72 0.01     
Aortic Regurgitation 
  
0.035         
Mild 122 ± 69.3 23 ± 76.7 
 
        
Moderate 8 ± 4.5 5 ± 16.7 
 
        
Sev ere 1 ± 0.6 0 ± 0.0 
 
        
Familiar  (N (%)) 25 ± 14.2 11 ± 36.7 0.006 3.08 0.00     
Atrial Fibrillation  (N (%)) 9 ± 5.1 3 ± 10.0 0.526 1.28 0.69     
Ischemic Cardiopathy  (N (%)) 2 ± 1.1 3 ± 10.0 0.023 3.03 0.07     
Cardiomiopathy  (N (%)) 0 ± 0.0 1 ± 3.3 0.314 49.46 < 0.001     
Chronic Kidney Disease  (N (%)) 1 ± 0.6 1 ± 3.3 0.674 5.85 0.09     
Chronic Obstructive Pulmo ry Disease  (N (%)) 4 ± 2.3 0 ±  0.0 0.906 0.00 1.00     
Hy pertension  (N (%)) 134 ± 76.1 25 ± 83.3 0.527 1.93 0.19     
Diabetes  (N (%)) 15 ± 8.5 2 ± 6.7 1 1.21 0.80     
Dy slipidemia  (N (%)) 40 ± 22.7 9 ± 30.0 0.527 1.58 0.24     
Implantable Cardiov erter Defibrillator  (N (%)) 3 ± 1.7 2 ± 6.7 0.322 4.97 0.01     
STEMI  (N (%)) 4 ± 2.3 6 ± 20.0 <0.001 0.47 < 0.001     
Smoke (N (%)) 24 ± 13.6 4 ± 13.3 1 0.55 0.86     
Statin  (N (%)) 53 ± 30.1 10 ± 33.3 0.889 0.40 0.36     
Stroke  (N (%)) 2 ± 1.1 0 ± 0.0 1 0.00 1.00     
Transient Ischemic Attack  (N (%)) 1 ± 0.6 1 ± 3.3 0.674 1.09 0.00     
Mitral Regurgitation (Mild-Moderate) 82 ± 46.6 20 ± 66.7 0.04 0.39 0.35     
Tricuspid Regurgitation (Mild-Moderate)  (N (%)) 100 ± 56.8 20 ± 66.7 0.417 0.41 0.08     
Ace Inhibitor  (N (%)) 107 ± 60.8 19 ± 63.3 0.951 0.41 0.37     
Alpha-Blocker  (N (%)) 13 ± 7.4 1 ± 3.3 0.672 0.74 0.94     
Antiaggregant  (N (%)) 16 ± 9.1 3 ± 10.0 1 0.61 0.52     
Anticoagulant  (N (%)) 15 ± 8.5 5 ± 16.7 0.29 0.50 0.20     
Acety lsalicylic Acid  (N (%)) 49 ± 27.8 12 ± 40.0 0.258 0.38 0.14     
Beta Blocker  (N (%)) 55 ± 31.2 17 ± 56.7 0.013 0.37 0.06     
Calcium Channel Blocker  (N (%)) 45 ± 25.6 5 ± 16.7 0.412 0.47 0.72     
Digox in  (N (%)) 1 ± 0.6 1 ± 3.3 0.674 1.03 0.07     
Diuretics  (N (%)) 24 ± 13.6 7 ± 23.3 0.273 0.46 0.18     
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Figure Legends 
 
Figure 1: Ascending aorta dimensions (mm) by time in patients with tricuspid or bicuspid aortic 
valve, according to repeated measures ANOVA.  
Figure 2: Trajectories of ascending aorta growth in patients with tricuspid or bicuspid aortic 
valve. Red line: superimposed polynomial quadratic linear growth model. 
Figure 3: Kaplan-Meier survival estimates. Outcome: time to aorta replacement. 
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